Clinical trials: Transfusion, active
Non Bleeding Patients With Thrombocytopenia
Platelet Transfusion Thresholds in Non-Bleeding Patients
This is a study of platelet transfusion thresholds in patients with thrombocytopenia without bleeding and benifits of transfusion in those critically ill patients to prevent bleeding
- Trial name
- NCT07915284
- Testing
- Platlet transfusion
- Where
- Egypt
- Volunteers
- 30 people
- Sponsor
- Sohag University
Transfusion-dependent β-thalassemia Patients
Evaluating the Clinical Efficacy and Safety of Luspatercept Combined With Thalidomide in the Treatment of β-TDT Patients
β-thalassemia is one of the most common inherited hemoglobinopathies worldwide and a major public health issue that severely impacts birth quality, human health, and social progress.
- Trial name
- NCT07338344
- Testing
- Luspatercept combined with low-dose thalidomide
- Where
- 8 sites in China
- Volunteers
- 78 people
- Sponsor
- Rongrong Liu
Anemia
Patient Blood Management Charité (PBM-Charité): Structured Detection, Differentiated Diagnostics and Therapy of Preoperative Anemia and Use of Machine Autotransfusion in Elective Interventions
The aim of patient blood management is to reduce the risks of perioperative anemia- and transfusion-associated complications by limiting the use and the need for allogeneic blood transfusion.
- Trial name
- NCT05146726
- Testing
- BARMER anemia treatment, NON-BARMER anemia treatment
- Where
- Germany
- Volunteers
- 2,700 people
- Sponsor
- Charite University, Berlin, Germany
Non-Transfusion-dependent Alpha-Thalassemia, Non-Transfusion-dependent Beta-Thalassemia
A Study to Investigate the Efficacy, Pharmacokinetics, and Safety of Mitapivat in Pediatric Participants With α- or β-Non-Transfusion-Dependent Thalassemia
The primary objective of this study is to compare the effect of mitapivat versus placebo on anemia in pediatric participants with alpha- or beta-non-transfusion-dependent thalassemia.
- Trial name
- ENERGIZEKids (NCT07517133)
- Testing
- Mitapivat
- Where
- 5 sites in United States
- Volunteers
- 45 people
- Sponsor
- Agios Pharmaceuticals, Inc.
Blood and Lymphatic Diseases
Long - Term Follow Up of Sickle Cell Disease and Beta-thalassemia Subjects Previously Exposed to BIVV003 or ST-400.
Primary Objectives: Long-term safety of BIVV003 in participants with severe sickle cell disease (SCD) and ST- 400 in participants with transfusion-dependent beta-thalassemia (TDT) Secondary Objectives: Long-term efficacy of the…
- Trial name
- NCT05145062
- Testing
- BIVV003, ST-400
- Where
- 7 sites in United States
- Volunteers
- 8 people
- Sponsor
- Sangamo Therapeutics
Myelodysplastic Syndromes
A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
The main aim of this study is to find out how well elritercept works in lowering the need for RBC transfusions. Other aims are to learn how well elritercept works in reducing the need for RBC transfusions over longer periods of…
- Trial name
- NCT06499285
- Testing
- Elritercept
- Where
- 182 sites in United States, Australia and 24 more
- Volunteers
- 225 people
- Sponsor
- Takeda
Preterm Birth Complication, Neonatal Morbidity and Mortality
Delayed Versus Immediate Cord Clamping in Preterm Birth
The goal of this study is to evaluate whether delayed cord clamping improves early neonatal outcomes compared with immediate clamping in preterm birth.
- Conditions
- Preterm Birth Complication, Neonatal Morbidity and Mortality, Cord Clamping, Delayed Cord Clamping
- Trial name
- PREM-CORD (NCT07699666)
- Testing
- Delayed Umbilical Cord Clamping, Immediate Umbilical Cord Clamping
- Where
- Tunisia
- Volunteers
- 200 people
- Sponsor
- Faculty of Medicine of Tunis
Transfusion-dependent Beta-Thalassemia
β-Thalassemia Treatment With KL003 Cell Injection
This is a non-randomized, open label, single-dose study in up to 41 participants with β-thalassemia major. The goal of this clinical trial is to evaluate the safety and efficacy of KL003 cell injection in subjects with…
- Trial name
- NCT06280378
- Testing
- KL003 Cell Injection Drug Product
- Where
- 2 sites in China
- Volunteers
- 41 people
- Sponsor
- Kanglin Biotechnology (Hangzhou) Co., Ltd.
Cardiac Disease, Bleeding Postoperative
Fresh Autologous Whole Blood Transfusion After Cardiopulmonary Bypass
Autologous blood transfused at the end of cardiopulmonary bypass will reduce total blood loss 24 hours after surgery and improve mitochondrial oxygen delivery measured by plasma succinate levels.
- Trial name
- NCT03204357
- Testing
- Fresh Autologous whole Blood, Standard of Care Expectant management of bleeding
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- University of Colorado, Denver
Blood Loss Anemia, Extracorporeal Membrane Oxygenation Complication
Red Blood Cell Transfusion in ECMO - A Feasibility Trial
Extracorporeal Membrane Oxygenation (ECMO) is an invasive and resource intense treatment used to support critically ill patients who have suffered severe cardiac arrest, cardiac failure or respiratory failure (including severe…
- Conditions
- Blood Loss Anemia, Extracorporeal Membrane Oxygenation Complication, Disability Physical, Cognitive Ability, General
- Trial name
- ROSETTA (NCT05814094)
- Testing
- Red Blood Cell Transfusion
- Where
- 2 sites in Australia
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Australian and New Zealand Intensive Care Research Centre
Leptospirosis
Preventive Strategies for Early and Late Complications of Leptospirosis
The goal of this clinical trial is to learn if complement factor I (CFI) works to predict development of complications in participants with leptospirosis.
- Trial name
- NCT07127718
- Testing
- Prophylactic Plasma Transfusion, Hemoperfusion, Extracorporeal Membrane Oxygenation
- Where
- 3 sites in Philippines
- Volunteers
- 678 people
- Sponsor
- National Kidney and Transplant Institute, Philippines
Sickle Cell Disease
Alternative Dosing And Prevention of Transfusions (ADAPT)
ADAPT is a prospective cohort study at Jinja Regional Referral Hospital (JRRH) primarily to assess the effect of hydroxyurea on blood transfusion utilization and secondarily to determine the feasibility of PK-guided hydroxyurea…
- Trial name
- NCT05662098
- Testing
- Hydroxyurea
- Where
- Uganda
- Volunteers
- 100 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Blood Transfusion Associated Adverse Reactions
Antihistamine for Prevention of HTR After Blood Primed CPB
This study will be a randomized, double-blinded, placebo-controlled study conducted at a university hospital. Forty children undergoing elective repair of a congenital heart defect will be included.
- Trial name
- HTR - CPB (NCT07536152)
- Testing
- Antihestamine
- Where
- Egypt
- Volunteers
- 40 people
- Sponsor
- Kasr El Aini Hospital
Sickle Cell Anemia, Beta-thalassemia Major
T-Cell Depleted Alternative Donor Bone Marrow Transplant for Sickle Cell Disease (SCD) and Other Anemias
The purpose of this study is to evaluate what effect, if any, mismatched unrelated volunteer donor and/or haploidentical related donor stem cell transplant may have on severe sickle cell disease and other transfusion dependent…
- Conditions
- Sickle Cell Anemia, Beta-thalassemia Major, Diamond-blackfan Anemia
- Trial name
- NCT03653338
- Testing
- CD3/CD19 depleted leukocytes, CD45RA depleted leukocytes, Hydroxyurea
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Paul Szabolcs
Beta-Thalassemia
ALS20-101 Lentiviral Gene Therapy for Beta Thalassemia
The main goal of this study is to find out if the blood disorder called transfusion-dependent beta thalassemia can be safely treated by modifying blood stem cells.
- Trial name
- NCT06364774
- Testing
- ALS20
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Children's Hospital of Philadelphia
Anemia Acute, Fatigue
ABC - A Post Intensive Care Anaemia Management Trial
On discharge from intensive care (ICU) patients are often severely anaemic (have a low level of haemoglobin (Hb) in their red blood cells (RBC)). Anaemia can persist for many months making patients feel tired and fatigued.
- Conditions
- Anemia Acute, Fatigue, Physical Disability, Quality of Life
- Trial name
- NCT04591574
- Testing
- Red Blood Cells (Transfusion)
- Where
- United Kingdom
- Volunteers
- 346 people
- Sponsor
- University of Edinburgh
Transfusion, Red Blood Cell
Restrictive Versus Liberal Thresholds for RBC Transfusion in ECMO
Rationale: In patients supported with extracorporeal membrane oxygenation (ECMO), transfusion of red blood cells (RBC) is very common.
- Conditions
- Transfusion, Red Blood Cell, Extracorporeal Membrane Oxygenation, Anemia
- Trial name
- TREC (NCT06560164)
- Testing
- Red Blood Cell transfusion
- Where
- 14 sites in Austria, Belgium and 2 more
- Volunteers
- 526 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Vaccination Reaction, Hepatitis B Virus Infection
Hepatitis B Vaccination After Neonatal Surgery
At present, whether the hepatitis B vaccine (HBV) can be vaccinated on time after neonatal surgery has become a common problem for children's families, neonatal surgeons, and vaccination departments, but there are few relevant…
- Conditions
- Vaccination Reaction, Hepatitis B Virus Infection, Digestive System Disorders of Fetus and Newborn, Blood Transfusion Complication
- Trial name
- NCT06023056
- Where
- China
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Children's Hospital of Chongqing Medical University
Anemia
A Study to Determine the Efficacy and Safety of Luspatercept in Adult Participants and to Evaluate the Safety and Pharmacokinetics in and Adolescent Participants With Alpha (α)-Thalassemia
The purpose of the study is to evaluate the efficacy and safety of luspatercept plus best supportive care (BSC) vs placebo plus BSC on anemia in adult participants with α-thalassemia hemoglobin H (HbH) disease and determine the…
- Trial name
- NCT05664737
- Testing
- Luspatercept
- Where
- 31 sites in China, Greece and 8 more
- Volunteers
- 189 people
- Sponsor
- Bristol-Myers Squibb
Diabetic Wounds, Platelet Rich Plasma
Allogeneic vs Autologous PRP for Diabetic Wounds in Renal Dysfunction: a Randomized Controlled Trial
Diabetic wounds are difficult to heal. Autologous platelets in diabetic patients with renal insufficiency have poor function. Allogeneic platelet plasma has a promising application prospect.
- Conditions
- Diabetic Wounds, Platelet Rich Plasma, Allogeneic Blood Transfusions, Renal Dysfunction
- Trial name
- NCT07020559
- Testing
- allogeneic platelet plasma, autologous platelet plasma
- Where
- China
- Volunteers
- 56 people
- Sponsor
- Peking University Third Hospital